BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 30910382)

  • 41. Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells.
    Zolov SN; Rietberg SP; Bonifant CL
    Cytotherapy; 2018 Oct; 20(10):1259-1266. PubMed ID: 30309710
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
    Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
    Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.
    Ramos CA; Rouce R; Robertson CS; Reyna A; Narala N; Vyas G; Mehta B; Zhang H; Dakhova O; Carrum G; Kamble RT; Gee AP; Mei Z; Wu MF; Liu H; Grilley B; Rooney CM; Heslop HE; Brenner MK; Savoldo B; Dotti G
    Mol Ther; 2018 Dec; 26(12):2727-2737. PubMed ID: 30309819
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy.
    Ghassemi S; Milone MC
    J Vis Exp; 2019 Dec; (154):. PubMed ID: 31904011
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Using Oncolytic Virus to Retask CD19-Chimeric Antigen Receptor T Cells for Treatment of Pancreatic Cancer: Toward a Universal Chimeric Antigen Receptor T-Cell Strategy for Solid Tumor.
    Chen C; Park AK; Monroy I; Ren Y; Kim SI; Chaurasiya S; Priceman SJ; Fong Y
    J Am Coll Surg; 2024 Apr; 238(4):436-447. PubMed ID: 38214445
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cancer Immunotherapy Using Chimeric Antigen Receptor Expressing T-Cells: Present and Future Needs of Clinical Cancer Centers.
    Gotti M; Defrancesco I; D'Angelo M; Basso S; Crotto L; Marinelli A; Maccalli C; Iaconianni V
    Front Immunol; 2020; 11():565236. PubMed ID: 33193333
    [TBL] [Abstract][Full Text] [Related]  

  • 47. T Cell Activators Exhibit Distinct Downstream Effects on Chimeric Antigen Receptor T Cell Phenotype and Function.
    Underwood S; Jin J; Shao L; Prochazkova M; Shi R; Song HW; Jin P; Shah NN; Somerville RP; Stroncek DF; Highfill SL
    Immunohorizons; 2024 Jun; 8(6):404-414. PubMed ID: 38864817
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of Cryopreservation on Autologous Chimeric Antigen Receptor T Cell Characteristics.
    Panch SR; Srivastava SK; Elavia N; McManus A; Liu S; Jin P; Highfill SL; Li X; Dagur P; Kochenderfer JN; Fry TJ; Mackall CL; Lee D; Shah NN; Stroncek DF
    Mol Ther; 2019 Jul; 27(7):1275-1285. PubMed ID: 31178392
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Manufacturing chimeric antigen receptor T cells from cryopreserved peripheral blood cells: time for a collect-and-freeze model?
    Palen K; Zurko J; Johnson BD; Hari P; Shah NN
    Cytotherapy; 2021 Nov; 23(11):985-990. PubMed ID: 34538575
    [TBL] [Abstract][Full Text] [Related]  

  • 50. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.
    Brudno JN; Maric I; Hartman SD; Rose JJ; Wang M; Lam N; Stetler-Stevenson M; Salem D; Yuan C; Pavletic S; Kanakry JA; Ali SA; Mikkilineni L; Feldman SA; Stroncek DF; Hansen BG; Lawrence J; Patel R; Hakim F; Gress RE; Kochenderfer JN
    J Clin Oncol; 2018 Aug; 36(22):2267-2280. PubMed ID: 29812997
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Preclinical Evaluation of Chimeric Antigen Receptor-Modified T Cells Specific to Epithelial Cell Adhesion Molecule for Treating Colorectal Cancer.
    Zhang BL; Li D; Gong YL; Huang Y; Qin DY; Jiang L; Liang X; Yang X; Gou HF; Wang YS; Wei YQ; Wang W
    Hum Gene Ther; 2019 Apr; 30(4):402-412. PubMed ID: 30693795
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gene Modification and Immunological Analyses for the Development of Immunotherapy Utilizing T Cells Redirected with Antigen-Specific Receptors.
    Ochi T; Maruta M; Hirano N
    Methods Mol Biol; 2019; 2048():27-39. PubMed ID: 31396926
    [TBL] [Abstract][Full Text] [Related]  

  • 53. AAVS1 site-specific integration of the CAR gene into human primary T cells using a linear closed-ended AAV-based DNA vector.
    Chen W; Tan L; Zhou Q; Li W; Li T; Zhang C; Wu J
    J Gene Med; 2020 Apr; 22(4):e3157. PubMed ID: 31901177
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CAR T cells for infection, autoimmunity and allotransplantation.
    Maldini CR; Ellis GI; Riley JL
    Nat Rev Immunol; 2018 Oct; 18(10):605-616. PubMed ID: 30046149
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chimeric Antigen Receptor T-Cells (CAR T-Cells) for Cancer Immunotherapy - Moving Target for Industry?
    Salmikangas P; Kinsella N; Chamberlain P
    Pharm Res; 2018 May; 35(8):152. PubMed ID: 29855723
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development of Inducible CD19-CAR T Cells with a Tet-On System for Controlled Activity and Enhanced Clinical Safety.
    Gu X; He D; Li C; Wang H; Yang G
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30400287
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development and Validation of a Good Manufacturing Process for IL-4-Driven Expansion of Chimeric Cytokine Receptor-Expressing CAR T-Cells.
    van Schalkwyk MCI; van der Stegen SJC; Bosshard-Carter L; Graves H; Papa S; Parente-Pereira AC; Farzaneh F; Fisher CD; Hope A; Adami A; Maher J
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359966
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.
    Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W
    Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Advanced Flow Cytometry Assays for Immune Monitoring of CAR-T Cell Applications.
    Blache U; Weiss R; Boldt A; Kapinsky M; Blaudszun AR; Quaiser A; Pohl A; Miloud T; Burgaud M; Vucinic V; Platzbecker U; Sack U; Fricke S; Koehl U
    Front Immunol; 2021; 12():658314. PubMed ID: 34012442
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice.
    Luskin MR; DeAngelo DJ
    Curr Hematol Malig Rep; 2017 Aug; 12(4):370-379. PubMed ID: 28656487
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.